Elan in deal with Abbott, AstraZeneca

Abbott Pharmaceutical and AstraZeneca have been granted the US rights to use Elan’s NanoCrystal Technology to develop fixed-dose combination products.

Under the terms of the agreement, Elan will receive payments upon the achievement of development, clinical, and regulatory milestones for such new products.

Additionally, Elan will receive royalty payments based on US sales of the products if successfully developed and commercialised.